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Decreased 02 consumption by PMNL from humans and rats with CRF:
Role of secondary hyperparathyroidism. Bactericidal ability of polymor-
phonuclear leukocytes (PMNL) is impaired in chronic renal failure
(CRF). This function of PMNL is mediated by the generation of
oxidizing radicals and the latter event requires 02 consumption by these
cells. The present study examined both basal and FMLP-stimulated rise
in cytosolic calcium ([Ca2]) and 02 consumption of PMNL from
normal subjects and hemodialysis patients and from CRF rats, and
evaluated the potential role of secondary hyperparathyroidism of CRF
on these properties of PMNL. Basal levels of [Ca2] were significantly
higher, and FMLP-induced increments in {Ca2]1 were significantly
lower in PMNL of both humans and rats with CRF than in normals.
Basal and FMLP-stimulated 02 consumption were significantly lower in
CRF subjects and rats than in normals. These derangements were
prevented by prior parathyroidectomy of CRF rats or by their treatment
with verapamil from day one of CRF. Also, therapy of rats with
pre-existing CRF with this drug reversed the abnormalities in lCa2I
and in 02 consumption of PMNL. The data indicate that: (1) CRF is
associated with derangements in the homeostasis of tCa2I of PMNL
and their oxygen consumption, (2) these abnormalities are, most likely,
mediated by the state of secondary hyperparathyroidism of CRF, and
(3) verapamil, which blocks the PTH-induced entry of calcium into
cells, and prevents as well as reverses these PMNL dysfunctions.
These results implicate the excess PTH of CRF in the genesis of the
defective bactericidal function of PMNL, and assign a new dimension
to PTH toxicity in CRF.
Certain data indicate that the bactericidal ability of polymor.
phonuclear leukocytes (PMNL) is impaired in chronic renal
failure (CRF) [1, 21. In order for the PMNL to kill bacteria,
these cells must first ingest the bacteria and subsequently kill
them by oxidizing agents generated during the respiratory burst
[3—5]. We, along with others, have shown that ingestion of
particles by PMNL from uremic patients [6—8] or rats with CRF
[9] is impaired. This derangement is mediated, at least in part,
by the state of secondary hyperparathyroidism of CRF which
causes a significant rise in the basal levels of cytosolic calcium
([Ca]1) and a significant reduction in ATP content of the
PMNL [8, 9]. Indeed, prevention of the changes in [Ca]1 and
ATP content of PMNL by parathyroidectomy of CRF rats or by
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their treatment with the calcium channel blocker, verapamil,
resulted in the normalization of phagocytosis [9].
The impaired ingestion of particles by PMNL in CRF could
explain the reduced bactericidal activity of these cells. How-
ever, it is also possible that CRF is associated with impaired
respiratory burst and hence reduced production of oxidizing
agents. Such an additional derangement provides another
mechanism underlying the impaired bactericidal activity of
PMNL in CRF. Available data on effect of CRF on respiratory
burst are controversial. Eckardt et al [10], utilizing chemilumi-
nesce technique and whole blood samples, reported enhanced
phorbol myristate acetate (PMA)-induced respiratory burst
activity in CRF and dialysis patients. In contrast, Hirabayashi
et al [11] found that PMA-induced production of H202 by
PMNL of hemodialysis patients is reduced, indicating impaired
respiratory burst. It is possible that, as in the case of particle
ingestion by PMNL, the secondary hyperparathyroidism of
CRF and the consequent metabolic derangements in PMNL [8,
91 interfere with their respiratory burst.
During the activation of the respiratory burst the PMNL
consumes oxygen, and therefore, oxygen consumption is an
indicator of the magnitude of the respiratory burst. We, there-
fore, examined basal and N-formyl-L-methionyl-L-leucyl-L-
phenylalamine (FMLP) stimulated oxygen consumption by
PMNL from CRF patients and from CRF rats with and without
excess PTH, and evaluated the usefulness of the calcium
channel blocker, verapamil, in preventing or reversing the
potential derangements in oxygen consumption by PMNL.
Methods
Experiments were done on both humans and animals. The
human studies were done in 18 hemodialysis patients (HD) and
15 normal subjects (NS). The age of HD patients ranged
between 20 to 55 (37.2 2.4) years and there were eight females
and 10 males. The duration of the HD treatment was 4 to 62
(27.4 4.1) months. The etiology of the renal failure was
essential hypertension in 10 patients, chronic glomerulonephri-
tis in five and unknown in three. In all patients, blood pressure
was maintained normal by appropriate medications which did
not include verpamil. Among the normal subjects there were
seven females and eight males, and their ages ranged between
24 and 45 (34.6 1.7) years. Peripheral venous blood was
drawn under sterile conditions into vacutainers containing 20 U
preservative-free heparin (Gibco Laboratories, Grand Island,
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New York, USA) per every 1.0 ml of blood. The blood samples
from dialysis patients were collected before the dialysis proce-
dure. These blood samples were used for the separation of
PMNL.
The animal studies were done in Sprague-Dawley rats weigh-
ing 320 to 480 g. They were fed rat chow diet (Wayne Research
Animal Diets, Chicago, Illinois, USA) throughout the study and
allowed to drink ad libitum. The diet contained 1.4% calcium
and 0.97% phosphorus. Two sets of studies were done. In the
first set, there were five groups of animals including: (a) normal
rats, (b) rats with chronic renal failure (CRF) of 42 days
duration, (c) normocalcemic parathyroidectomized (PTX) rats
with CRF of 42 days duration (CRF-PTX rats), (d) rats with
CRF of 42 days duration treated daily with verapamil from day
one of CRF (CRF-VER rats), and (e) normal rats treated with
verapamil for 42 days (normal-VER rats).
In the second set of animal studies, CRF was maintained for
84 days. On day 42 of CRF, the rats were randomized to two
groups which were matched in regard to their creatinine clear-
ance and blood levels of PTH. One group began to receive
verapamil from day 42 through day 84 of CRF, while the second
group received no verapamil.
Parathyroidectomy was done by electrocautery, and the
success of the procedure was ascertained by a decrease in
plasma levels of calcium of at least 2 mg/dl. The PTX rats were
freely allowed to drink water containing 50 g/liter of calcium
gluconate. This procedure is adequate to normalize plasma
calcium in PTX rats. Animals that did not display a fall in
plasma calcium of 2 mg/dl or more after PTX, and the PTX rats
that did not attain normocalcemia with drinking calcium con-
taining water were discarded and not used in the study. Seven
days after PTX, the animals underwent right partial nephrec-
tomy through a flank incision; a week later, a left nephrectomy
was performed. This nephrectomy procedure was also per-
formed in rats with intact parathyroid glands. Verapamil (Isop-
tin, Knoll, AG, Ludwigshafen, Germany) was injected subcu-
taneously in a dose of 0.1 jig/g body weight twice daily. Two
days before the experiments, the rats were housed in metabolic
cages for the collection of two 24-hour urine outputs which
were used for the measurement of creatinine clearance. The
latter was also measured at days 40, 41, 82 and 83 of CRF in rats
that were maintained for 84 days. On the day of the experiment,
the rats were put under light ether anesthesia and blood was
drawn directly from the heart under sterile conditions and
placed into sterile test tubes containing 100 U of preservative-
free heparin (Gibco) per 1.0 ml of blood.
The separation of PMNL from peripheral blood was made
according to the method described by Ferrante and Thong [121
with certain modifications. The details of the method of sepa-
ration of PMNL from blood of HD patients and NS have
already been reported from our laboratory [8]. In brief, 3.0 ml of
fresh heparinized blood was placed over two layers Ficoll-
hypaque solution in 15 ml conical polypropylene tubes. The
bottom layer was made of 3 ml of Mono-Poly Resolving
Medium with density of 1.114 g/ml (Flow Laboratories, Inc.,
McLean, Virginia, USA) and second layer of 1.0 ml Isolymph
with density of 1.077 g/ml (Gallard-Schlesinger Industries Inc.,
Carle Place, New York, USA). The tubes were centrifuged at
1270 X g for 45 minutes at room temperature. This procedure
resulted in the separation of mononuclear and polymorphonu-
clear cells into two distinct bands with the red blood cell pellet
at the bottom of the tube. The PMNL were aspirated with
Pasteur pipette and washed twice in Hank's balanced salt
solution (HBSS). Cells from two to three animals were pooled
from each study. Cell purity determined by Wright's staining
was greater than 97% and cell viability assayed by the trypan
blue exclusion method exceeded 98%. Difficulty in the separa-
tion of PMNL was encountered in few blood specimens and this
was overcome by extending the time of centrifugation. To
remove red blood cells that might have remained with PMNL
samples obtained from humans or rats, hypotonic lysis with 3
ml of 0.2% NaCl was done for 30 seconds followed by the
addition of 3 ml of 1.6% NaCl. The samples were centrifuged
for 15 minutes at 250 x g. This procedure was done twice. The
PMNL pellet was resuspended in adequate volume of calcium-
free Hank's solution containing 20 mrvi HEPES and 5.6 mM
glucose to give 2 x 108 PMNL/ml. The samples were kept on
ice and used for the measurements of basal and FMLP-stimu-
lated oxygen consumption and cytosolic calcium ([Ca2]1).
Oxygen consumption was determined polarographically by
means of a Clark oxygen electrode (Gilson Medical Electronics,
Middelton, Wisconsin, USA), fitted to a plexiglass chamber of
2.0 ml capacity as described originally by Chance and Williams
[131. The method used for this measurement in PMNL was
described by Rossi et al [14]. First 2.0 ml of Hank's solution
containing 1.25 m of CaC12 was placed in the plexiglass
chamber for 5 to 10 minutes at 37°C; thereafter 600 d of this
solution was removed and 500 d of the PMNL suspension (1 x
l0 cells) and 50 l of KCN was added to give a final concen-
tration of 1 m. The latter was added to inhibit mitochondrial
oxygen consumption. Basal oxygen consumption by PMNL
was monitored for five minutes followed by the addition of 50 iil
of FMLP to give a final concentration of 2 .tM inside the
chamber. Oxygen consumption was then monitored for 10
minutes and calculated using a solubility coefficient of 0.024
p,mol/ml of medium and expressed as nmol 02/2 X iO PMNL/
mm.
Resting levels of [Ca241, of the PMNL and FMLP-induced
rise in [Ca2]1 were estimated with Fura2-AM (Sigma Chemical
Co., St. Louis, Missouri, USA). A sample of 5 x 106 PMNL
was washed with solution I containing in mM: NaCl, 132; KCI,
3; MgSO4, 1; NaH2PO4, 1.2; D-glucose, 10; HEPES, 10; CaC12
0.02 (pH was adjusted to 7.4 with Tris buffer) and spun at at 300
x g for 15 minutes. The pellet was resuspended in 490 d of the
above solution and 10 d of Fura2-AM dissolved in DMSO
giving a final concentration of 4 iM of Fura2. The mixture was
then incubated in a water bath of 37°C for 30 minutes. After this
incubation, the cells were washed and resuspended in solution
I. Measurements of [Ca2]1 were done with Perkin Elmer
fluorescence spectrophotometer model LS SB (Perkin-Elmer
Corp., Norwalk, Connecticut, USA) at excitation wavelength
of 340 nm and 380 nm and emission wavelength of 510 nm with
a slit of 10 and 20 mm, respectively. An aliquot of 100 d of
PMNL suspension was added to a spectrophotometer cuvette
containing 1.9 ml of solution II, which was the same as solution
I except for its CaCl2 concentration being 1 msi. Autofluores-
cence from cells and/or added reagents was monitored during
each experiment and was not found to be a significant factor.
Maximal fluorescence (Fmax) and minimal fluorescence (Fmjn)
were measured with 0.05% Triton and 5 ms EGTA in Tris Base
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Table 1. Basal levels and FMLP-induced changes in [Ca2] and oxygen consumption of PMNL of humans and rats with chronic renal failure
N
[Ca2]1 flM [Ca2I.
After FMLP
nM
[Ca2 ÷]
basal [Ca2I1
ratio
Oxygen consumption
nmol 02/2 x io PMN/min
After
Basal FMLP
After
Basal FMLP
I. Human studies
II.
Normal subjects
Hemodialysis patients
Rat studies
15
18
57 1.1 198 7.6
68 1.l 182 3.3
170 7.4
114 2.9a
2.45 0.13
1.70 O.O4
5.8 0.42 61 0.3
3.5 0.43a 32 l.8a
A. 6 Week rat studies
Normal 20 104 1.3 197 1.9 93 2.7 0.87 0.03 3.2 0.10 29 0.5
CRF 20 133 3.l 189 2.9 56 4.1 0.43 0.03 2.1 0.l6 14 0.7w
CRF-PTX 12 103 1.6 196 2.3 93 3.1 0.90 0.04 3.0 0.16 27 0.8
CRF-VER 19 103 1.0 188 3.0 85 3.0 0.82 0.02 2.9 0.18 26 0.7
Normal-VER 20 105 2.2 190 2.0 85 2.3 0.83 0.03 2.9 0.13 30 1.0
B. 12 Week rat studies
CRF without VER 17 141 3.1k 190 1.9 49 0.3 0.34 0.03 2.2 0.08a 14 o.7
CRF with 6 weeks VER 16 106 2.0 190 4.9 84 3.0 0.78 0.03 3.0 0.20 23 1.1
Data are presented as mean SE.
a p < 0.01 vs. normal subjects (Human studies), vs. normal, CRF-PTX, CRF-VER, and Normal-VER (6 week rat studies) and vs. CRF-VER
(12 week rat studies)
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Fig. 1. Basal levels of [Ca'] of PMNL of normal subjects and
hemodialysis patients. Each datum point represents one individual and
brackets denote mean 1 SE. The values between the two groups are
significantly (P < 0.01) different.
buffer (pH 8.0), respectively. Calculation of [Ca2}1 was done
using the Grynkiewicz equation and the dissociation constant
for Ca2tFura2 was assumed to be 225 flM 1151.
Themeasurement of calcium in plasma was made with Perkin
Elmer atomic absorption spectrophotometer model 503 (Perkin
Elmer Corp.) and those of creatinine and phosphorus by
Technicon autoanalyzer (Technicon Instrument, Inc., Tarry-
town, New York, USA). PTH levels in serum from rats were
determined by INS-PTH immunoassay kit (Nichols Institute
Dignostics, San Juan Capistrano, California, USA). This assay
recognizes the aminoterminal fragment of PTH. The lowest
detectable level is 3 pg/mI. The interassay variation is 7.3% and
the intrassay variation is 4%.
Normal Hemodialysis
subjects patients
Fig. 2. Oxygen consumption in response to FMLP by PMNL from
normal subjects and hemodialysis patients. Each datum point repre-
sents one patient and brackets denote mean 1 SE. The values between
the two groups are significantly different.
PTH in humans was measured with radioimmunoassay uti-
lizing sheep anti-sera 478 (supplied by Dr. Claude Arnaud),
'251-labeled bovine PTH and pooled sera from patients with
renal failure as standard. This antibody reacts predominantly
with an immunologic determinant in the carboxyl region of
human PTH, and it detects both the intact hormone and its
carboxyterminal fragment. The values for this assay in 63
normal subjects ranged from undetectable to 15 (5.7 0.7)
dEq/ml. The blood levels of PTH were detectable in 33 of the
63 (52%) normal subjects. Elevated blood levels of PTH were
found in all 60 patients with CRF. The lower unit of detectabil-
ity is 1 p.lEq/ml.
Statistical evaluation was made with one way analysis of
variance and Tukey's HSD (Honest Statistical Difference) for
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Table 2. Biochemical data in rats with six weeks of chronic renal failure
N
Body weight
g
Plasma mg/dL Creatinine
clearance
pL/min/lOO g
Serum PTH
pg/mLCalcium Phosphorus Creatinine
Normal 20 347 4.8 9.4 0.1 8.1 0.06 0.40 0.01 453 10 24 2.5
CRF 20 346 3.9 9.3 0.1 7.5 011b 1.15 0.028 161 108 61 34
CRF-PTX 12 354 7.8 9.3 0.1 8.0 0.10 1.13 0.038 167 ioa 13 Ø•5C
CRF-VER 19 340 4.8 9.4 0.1 7.1 007b 1.12 0.028 150 ioa 54 3.6a
Normal-VER 20 341 4.9 9.5 0.1 8.1 0.04 0.40 0.01 443 10 21 1.1
Data are presented as mean I SE.
a P < 0.01 vs. normal and normal-VER
b P < 0.01 vs. normal CRF.PTX and normal-VER
C P < 0.01 vs. other groups
170
Results
Studies in humans
The HD patients have markedly elevated serum levels of
PTH (486 104 dEq/ml). There were no significant differences
in plasma levels of calcium between the NS and HD patients
(9.4 0.23 vs. 8.9 0.5 mg/dl). The plasma levels of phospho-
rus in HD patients (4.7 0.20 mgldl) was significantly (P <
0.01) higher than in NS (3.5 0.11 mgldl). The resting levels of
[Ca2]1 in PMNL of HD patients were significantly (P < 0.01)
higher than those in NS (Table 1, Fig. 1). The rise (A) in [Ca2111
as well as the ratio of A [Ca2]1/basal[Ca2]1 after FMLP were
significantly (P < 0.01) smaller in HD patients than in NS (Table
1). Both basal and FMLP stimulated oxygen consumption in
PMNL of HD patients were significantly (P < 0.01) lower than
in NS (Table 1, Fig. 2).
Studies in rats with six weeks of CRF
Table 2 provides the biochemical data in these rats. There
were no significant differences in body weight among the rats of
the five groups studied. The 5/6 nephrectomy produced signif-
icant (P < 0.01) increments in plasma levels of creatinine and
significant (P < 0.01) decrements in creatinine clearance. In-
deed, the serum levels of creatinine were almost three times
higher and the values of creatinine clearance three times lower
in CRF, CRF-PTX and CRF-VER than in normal and normal-
VER rats. There were no significant differences between these
parameters among the CRF, CRF-PTX and CRF-VER animals.
Similarly, the plasma levels of calcium were not different among
the five groups of animals. The plasma levels of phosphorus
were significantly (P < 0.01) lower in CRF and CRF-VER rats
than in normal, CRF-PTX and normal-VER animals. The serum
levels of PTH were significantly (P < 0.01) elevated in CRF and
CRF-VER animals than in normal, CRF-PTX and normal- VER.
Resting levels of [Ca2] in PMNL of rats with six weeks of
CRF were significantly (P < 0.01) higher than those in normal,
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Fig. 3. Basal levels of [Ca2 of PMNL from
the five groups of rats studied for six weeks.
Each datum point represents one study of
PMNL pooled from 2 to 3 rats. Brackets
denote mean 1 SE. The values in CRF rats
are significantly (P < 0.01) higher than those
CRF-VER Normal-VER in the other 4 groups of animals.Normal CRF CRF-PTX
multiple comparison between groups, and unpaired t-test for
comparison of parameters within each group. Data are ex-
pressed as mean SE.
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• -m-:.. Fig. 5. Oxygen consumption in response to:: FMLP by PMNL from the five groups of rats
studied for six weeks. Each datum point
• represents one study of PMNL pooled from 2
to 3 rats. Brackets denote mean 1 SE. The
values in CRF rats are significantly (P < 0.01)
lower than those in the other 4 groups of
Normal CRF CRF-PTX CRF-VER Normal-VER animals.
CRF-PTX, CRF-VER and normal-VER rats and there were no
significant differences between the values of PMNL [Ca21 in
the latter four groups of animals (Table 1, Fig. 3). FMLP
produced significantly (P < 0.01) smaller rise in [Ca2]1 (Table
1, Fig. 4) and in oxygen consumption (Table 1, Fig. 5) in PMNL
of rats with CRF than in those of the other four groups, and
there were no differences in these parameters among normal,
CRF-PTX, CRF-VER and normal-VER. Basal levels of oxygen
consumption in PMNL of CRF rats was significantly lower than
in PMNL of the other four groups (Table I).
Twelve week rat studies
The biochemical data in these rats are provided in Table 3. At
the time of randomization (6 weeks of CRF), there were no
significant differences in the body weight, plasma levels of
calcium, phosphorus and creatinine, serum levels of PTH and
creatinine clearance in the animals which were to be maintained
for 12 weeks of CRF with or without treatment with verapamil.
Similarly, these parameters were not different between the two
subgroups at the time of study (12 weeks of CRF).
The resting levels of [Ca2] of PMNL in 12 weeks CRF rats
were significantly (P < 0.01) higher than in those treated with
verapamil for the last six weeks of CRF (Table 1, Fig. 6). Basal
levels of oxygen consumption by PMNL from 12 weeks CRF
rats was significantly (P < 0.01) lower than from CRF-V rats.
FMLP caused a significantly (P < 0.01) smaller rise in [Ca2]1
(Table 1, Fig. 7) and oxygen consumption (Table 1, Fig. 8) in
PMNL of 12 weeks CRF rats than in those treated with
verapamil for the last six weeks of CRF.
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Table 3. Biochemical data of twelve week rat studies
Body weightN g
Plasma mgldL Creatinine
clearance
LImin/1OO g
Serum PTH
pg/mLCalcium Phosphorus Creatinine
I. At time of randomization (6 weeks of CRF)
Rats to be maintained without verapamil 17 363 5.3 9.4 0.1 7.2 0.06 1.10 0.04 150 4 71 6.1
Rats to be treated with verapamil 16 370 2.1 9.5 0.1 7.1 0.05 1.09 0.04 155 8 65 6.4
II. After 12 weeks of CRF
CRF only 17 443 4.7 9.2 0.2 6.8 0.15 1.12 0.18 138 2 68 5.9
CRF with verapamil treatment 16 432 1.9 9.0 0.2 6.8 0.10 1.00 0.08 174 8 69 5.5
Data are presented at mean 1 SE.
70j,
0 12wkCRF 12wkCRF
6wkVER
Fig. 6. Basal levels of [Ca2 of PMNL of CRF rats studied for 12
weeks. Each datum point represents the study of PMNL pooled from 2
to 3 rats. Brackets denote mean 1 SE. The values of 12 weeks (wk)
rats are significantly (P < 0.01) higher than those in 12 weeks CRF rats
treated with verapamil for the last 6 weeks.
Discussion
The results of the present study demonstrate that PMNL
from both HD patients and rats with CRF have lower basal and
FMLP-stimulated oxygen consumption than corresponding
normal values. This defect is most likely mediated by the
secondary hyperparathyroidism associated with CRF, since
parathyroidectomy of CRF-rats and the prevention of the rise in
serum PTH levels by this procedure normalized both basal and
the FMLP-stimulated oxygen consumption.
The mechanism(s) through which excess PTH exerts its
deleterious effects on oxygen consumption could be multiple.
However, one consequence of chronic excess PTH, such as an
elevation in basal [Ca21i, could play a major role in this defect.
It has been shown that chronic excess of PTH in the presence
[8, 9, 16—201 or absence of CRF [17, 21] is associated with a rise
in basal levels of [Ca2} in many cells, including pancreatic
islets [16, 211, brain synaptosomes [17], T cells [181, B cells [19],
PMNL [8, 9] and platelets [20]. This elevation in basal [Ca2]
of these cells has been implicated in the disturbances of their
function in CRF [8, 9, 16, 21, 22], since the prevention of this
rise in basal [Ca21 was followed by normalization of function
despite CRF [9, 22—24]. The present study again demonstrates
12wkCRF I2wkCRF
6wkVER
Fig. 7. The change in [Ca2], in response to FMLP in PMNL of CRF
rats studied for 12 weeks. Each datum point represents one study of
PMNL pooled from 2 to 3 rats. Brackets denote mean I SE. The
values in 12 weeks (wk) CRF rats are significantly (P < 0.01) lower than
those in 12 weeks CRF rats treated with verapamil for the last 6 weeks.
that PMNL of the HD patients and rats with CRF have elevated
basal levels of [Ca2], and this derangement could be respon-
sible for their impaired oxygen consumption. Indeed, the treat-
ment of CRF rats with verapamil from day one of CRF
prevented the elevation in basal [Ca2] as well as the abnor-
mality in oxygen consumption.
It is of interest that verapamil treatment of CRF rats not only
prevented the abnormalities in [Ca2] and oxygen consumption
in PMNL when the drug was given from day one of CRF, but
also reversed these derangements in PMNL when the drug was
given to rats with pre-existing CRF. This observation has
important clinical implications and points toward the usefulness
of this calcium channel blocker in the management of already
developed manifestations of the uremic syndrome. Indeed,
Thanakitcharu et al [25] have also shown that treatment of rats
with pre-existing renal failure with verapamil reversed the
CRF-induced abnormalities in the metabolism and function of
pancreatic islets.
It is of interest that verapamil treatment of normal rats did not
affect the [Ca2] of their PMNL. Similar observations were
found in pancreatic islets [24] and brain synaptosomes [17]. A
decrease in calcium entry into cells of normal animals by
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12wkCRF 12wkCRF
6 wk VER
verapamil is counterbalanced by a decrease in calcium extru-
sion out of the cells due to a modest adaptive decrease in the
Vmax of Ca2 ATPase [24, 26]. It is possible that a similar
phenomenon occurs in PMNL of normal rats treated with
verapamil.
Certain data suggest that PMNL may not have L-type volt-
age-dependent calcium channels [27] which are blocked by
verapamil [281. On the other hand, Schimchowitz and Spilberg
[29] showed that 45Ca influx in PMNL is inhibited by verapamil.
Therefore, our finding that verapamil prevented the rise in
[Ca2]1 in PMNL of CRF rats suggests that either L-type
calcium channels do exist in PMNL, or other types of calcium
channels may be present in PMNL [30] and are affected by
verapamil, or the drug may affect [Ca2 by other mechanisms,
the nature of which has not been elucidated by our studies.
It has been proposed that for an agonist to elicit an appropri-
ate physiologic response, it should induce an adequate calcium
signal and an appropriate [Ca2]1/basal[Ca2] ratio [31], A
rise in basal [Ca2]1 of cells may interfere with the magnitude of
the calcium signal and/or the [Ca2]1/basal[Ca2] induced by
an agonist and hence an impairment of the cell response to the
agonist. Indeed, an elevated basal [Ca2] of pancreatic islets of
CRF rats displayed a smaller rise in [Ca2]; and in [Ca2I1/
basal[Ca2]1, and impaired insulin secretion in response to
potassium [32] or glucose [33] as compared to islets from
normal rats and with normal basal [Ca2]. Normalization of the
basal [Ca2]1 in the CRF islets resulted in restoration of the
calcium signal, and insulin secretion in
response to those insulin secretogogues [32, 33]. Also, PMNL
from CRF patients had elevated basal levels of [Ca2]1 and
smaller calcium signal and in response to
monoclonal antibody 3G8 with specificity anti-CD 16 as com-
pared to PMNL from normal subjects [81.
FMLP, after binding to its receptor on the PMNL [34],
induces a rise in [Ca2] [35, 36] which in turn activates the
respiratory burst [36, 37] and hence an increase in oxygen
consumption [38]. It is possible, therefore, that the elevated
basal levels of [Ca2] in PMNL from humans or rats with CRF
interferes with the calcium signal and/or i[Ca2]1/basal[Ca2]1
induced by FMLP and hence in impaired oxygen consumption.
Indeed, our data show that both the magnitude of the calcium
signal and the z[Ca2J1/basa1[Ca2J as well as the rise in
oxygen consumption in PMNL of patients and animals with
CRF in response to FMLP are significantly (P <0.01) smaller
than in PMNL from normal subjects and normal rats. Further,
the normalization of basal [Ca2I1 in PMNL of CRF rats by
parathyroidectomy or by treatment with verapamil resulted in
restoration of the responses in [Ca2]1 as well as in oxygen
consumption to FMLP. Additional support for this notion is
found by the data of Korchak et al [37], demonstrating that the
buffering of the FMLP-induced rise in [Ca2] of PMNL is
associated with a significant reduction in generation of oxygen
radicals and thus in oxygen consumption. Further, calcium
ionophore that increase [Ca2]1 trigger activation of respiratory
burst [39, 40].
Although the above-cited arguments suggest a cause and
effect relationship between the rise in [Ca2]1 and oxygen
consumption, other data challenge this proposition. Grinstein
and Furuya [41], using electropermeabilized PMNL, found that
the FMLP-induced oxygen consumption persisted even in cell
depleted intracellular [Ca2i. They concluded that changes in
[Ca211 are not required for FMLP-stimulated respiratory burst.
Studies by O'Flaherty et al [42] also suggested that calcium
transient may not be required but may potentiate the FMLP
receptor-mediated respiratory burst. They also suggested that
some calcium pool may affect receptor expression in PMNL. It
is, therefore, theoretically possible that a rise in basal levels of
[Ca2]1 in CRF may be associated with reduced expression of
FMLP receptors in PMNL, resulting in a reduced rise in [Ca2
and in reduced oxygen consumption without necessarily a
cause and effect between these two parameters. Also, one can
speculate that the elevated basal levels of [Ca2] of PMNL in
CRF may induce damage to these cells through activation of
proteases and lipases, and therefore impede their FMLP-in-
duced oxygen consumption.
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